News Breaks |
|
|
| January 3, 2013 |
| 05:05 EDT |  | BAYRY, ONXX | Bayer, Onyx announce Phase 3 DECISION trial of Nexavar meets primary endpoint
Bayer HealthCare Pharmaceuticals (BAYRY) and Onyx Pharmaceuticals (ONXX) announced that a Phase 3 trial of Nexavar tablets in patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement of progression-free survival. The study, called DECISION, evaluated the efficacy and safety of Nexavar compared to placebo. Adverse events were generally consistent with the known profile for Nexavar. Data from this study are expected to be presented at an upcoming medical meeting. |
|
|
News For BAYRY;ONXX From The Last 14 Days Check below for free stories on BAYRY;ONXX the last two weeks. |
|
|
| May 17, 2013 |
| 06:33 EDT |  | BAYRY | American Thoracic Society to hold a conference
 Subscribe for More Information |
|
| May 15, 2013 |
| 11:43 EDT | | BAYRY | Bayer announces FDA approval for Xofigo as CRPC treatment
Subscribe for More Information |
|
| May 8, 2013 |
| 08:52 EDT |  | ONXX | Onyx Pharmaceuticals price target raised to $115 from $105 at Maxim
Subscribe for More Information |
|
| May 7, 2013 |
| 17:25 EDT | | BAYRY | Bayer commences cash tender offer for Conceptus shares
Subscribe for More Information |
|
| 16:01 EDT |  | ONXX | Onyx Pharmaceuticals reports Q1 EPS (47c), consensus (47c)
Reports Q1 revenue $145.5M, consensus $134.36M. |
|
| May 6, 2013 |
| 07:18 EDT | | BAYRY | American Congress of Obstetrics and Gynecology to hold annual meeting
Subscribe for More Information |
|
|
|
|
|
